FeesSafety
Pluang+

U.S. spot Bitcoin ETFs see $65.4M net outflows, led by BlackRock's IBIT on Oct 12.

Market News
13 Oct 2026, 07:05 WIB
Tokenpost
View Source
Bearish
U.S. spot Bitcoin ETFs see $65.4M net outflows, led by BlackRock's IBIT on Oct 12.

On October 12, U.S. spot Bitcoin ETFs experienced a combined net outflow of $65.4 million, with BlackRock's iShares Bitcoin Trust ETF (IBIT) accounting for the entire amount as the largest single-day net outflow. Despite this, IBIT's cumulative net inflows have reached $65.668 billion, and total net assets across all U.S. spot Bitcoin ETFs stand at $106.058 billion, representing 6.35% of Bitcoin's total market cap. These ETF flows reflect share creation and redemption activities rather than direct Bitcoin purchases by BlackRock. IBIT offers investors exposure to Bitcoin through brokerage accounts and is also used by some institutions in basis trades to capitalize on price differences between spot and futures markets.

U.S. spot Bitcoin ETFs net outflow of $65.401 million is the subject, with Pluang market data as context. As of Oct 13, 2026 10:51 WIB, out of 50 major cryptocurrencies priced on Pluang, 5 rose and 44 fell. Notable movers include COTI at Rp224 with a -6.47% change and 78% sell order activity, Kusama (KSM) at Rp85,402 down 6.18% with 90% buy order activity, and Filecoin (FIL) at Rp20,676 down 5.69% with 68% buy order activity.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
1 hour ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
1 hour ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
1 hour ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
1 hour ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App